Skip to main navigation
Skip to search
Skip to main content
Universidad del Rosario Home
English
Español
Home
Profiles
Research units
Research output
Projects
Press/Media
Datasets
Prizes
Activities
Impacts
Student theses
Search by expertise, name or affiliation
New Treatment Modalities for Neovascular Age-Related Macular Degeneration
Patricio G. Schlottmann
, Arturo A. Alezzandrini
, Marcelo Zas
, Francisco J. Rodriguez
, José D. Luna
, Lihteh Wu
School of Medicine and Health Sciences
urosario
Research output
:
Contribution to Journal
›
Review article
›
peer-review
31
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'New Treatment Modalities for Neovascular Age-Related Macular Degeneration'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Anti-vascular Endothelial Growth Factor (anti-VEGF)
100%
Neovascular Age-related Macular Degeneration (nAMD)
100%
New Treatment Options
100%
Clinical Trials
66%
Vision Loss
66%
Vascular Endothelial Growth Factor
66%
Gene Therapy
33%
Retina
33%
Older Adults
33%
Advanced Stage
33%
Phase II Study
33%
High Efficacy
33%
Neovascular Membrane
33%
Phase II Trial
33%
Retina Specialists
33%
Treatment Regimen
33%
Armamentarium
33%
Age-related Macular Degeneration
33%
Early Development
33%
Treatment Burden
33%
Anti-vascular Endothelial Growth Factor Therapy
33%
Squalamine
33%
Abicipar Pegol
33%
Brolucizumab
33%
Unmet Medical Need
33%
Vascular Endothelial Growth factor-C (VEGF-C)
33%
Promising Treatment
33%
Neovascular
33%
Long-term Durability
33%
Visual Gain
33%
Pharmacology, Toxicology and Pharmaceutical Science
Vasculotropin
100%
Wet Macular Degeneration
100%
Clinical Trial
40%
Visual Impairment
40%
Age Related Macular Degeneration
20%
Vasculotropin C
20%
Squalamine
20%
Abicipar pegol
20%
Brolucizumab
20%
Material Science
Gene Therapy
100%